



Demographics and socioeconomic

Total Population (in 1000) (2020)	11,326.62
Population <1 year of age (in 1000) (2020)	100.98
Population 1 year of age (in 1000) (2020)	109.54
Population <5 years of age (in 1000) (2020)	571.28
Women of childbearing age (in 1000) (2020)	6,952.14
Infant Mortality Rate (per 1000 live births) (2018)	4.0
Gross national income (US\$ per capita) current value (2020)	0.0
National Health Expenditure Public (2018)	9.9
National Health Expenditure Private (2018)	1.2

Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 2020-2020.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 9 times in 2020.
- 99% of spending on routine immunization is financed using government funds.
- 98% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	1999
Hepatitis B	1990
HPV	
Influenza	1998
MMR1	1986
MMR2	2004
Pentavalent	2006
Pneumococcal Conjugate	
Rotavirus	
Tdap	
Tetavalent DPT-Hib or DPT-HepB	2005
Yellow Fever	

Immunization Schedule

	Doses					
	1	2	3	4	5	6
CUB						
BCG	B					
HepB pediatric	B	M2	Y1			
DTP-Hib						
DTP-Hib-HepB	M2	M4	M6	M18		
DTP-Hib-IPV						
DTP-Hib-HepB-IPV						
DTP	M2	M4	M6	M18		
Influenza pediatric	>M6					
IPV						
OPV	<Y1	Y1	Y2	Y9		
MMR	Y1	Y6				
Pneumoco conjugate						
Rotavirus						
Td						
Tdap						
HPV						

Vaccination Coverage




Surveillance indicators

Acute flaccid paralysis (AFP)	2020
Number of AFP suspected cases	21
AFP rate per 100,000 population <15 years old	1.16
% of cases with 1 adequate samples	95
% of cases investigated within <48 hours	81
% sites reporting	100


Measles-rubella (MR)	2020
Number of MR suspected cases	1,540
% of cases with adequate investigation	100
% of cases with adequate blood samples	100
% of samples received in laboratory <=5 days	100
% of laboratory samples results <=4 days	100




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend
 NB/nb-newborn
 M/m -month
 Y/y-year
 WCBA-women of childbearing age
 ● with stockout
 ● no stockout

Vaccine Stockout

CUB	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes						●	●	
BCG	●	●	●	●	●	●	●	●
Disposable syringes	●	●						
DTP	●	●	●	●	●	●	●	●
HepB	●	●	●	●	●	●	●	●
Hib	●	●	●	●	●	●	●	●
Influenza	●	●	●	●	●	●	●	●
IPV				●	●	●	●	●
Measles	●	●	●	●	●	●	●	●
Pneumo. conjugate								
Polio	●	●	●	●	●	●	●	●
Reconst. syringes		●						
Rotavirus								
Safety boxes	●	●		●		●	●	●
Tdap								
TT	●	●	●	●	●	●	●	●
Yellow fever	●		●		●		●	●